Is Now a Good Opportunity to Include Thermo Fisher Stock in Your Investment Portfolio?

Thermo Fisher Scientific: Growth Strategies and Market Challenges

Thermo Fisher Scientific Inc. (TMO) continues to demonstrate its dedication to sustainable expansion through a series of targeted acquisitions. The company’s performance is also buoyed by robust demand across its key markets. However, challenges such as unfavorable currency fluctuations and intense industry rivalry present ongoing obstacles for the business.

Over the past year, shares of this Zacks Rank #3 (Hold) company have declined by 2.4%, outpacing the broader medical products sector’s 4.3% drop. In contrast, the S&P 500 index saw a notable gain of 21.9% during the same period.

As a leading provider of medical and laboratory equipment, Thermo Fisher boasts a market value of $192.62 billion. The company’s earnings yield stands at 4.8%, outperforming the sector’s negative 0.7%. Impressively, TMO has exceeded earnings expectations for the last four quarters, averaging a 2.8% positive surprise.

Examining the Growth Drivers

Strong Performance Across End Markets

Thermo Fisher’s biosciences and bioproduction divisions have recently scaled up operations to address global vaccine production needs. In the fourth quarter of 2025, the Pharma and Biotech segment achieved high single-digit growth, fueled by the bioproduction business and the research and safety market channel.

For the full year, the Industrial and Applied segment benefited from solid results in the research and safety market channel and ongoing momentum in electron microscopy. Meanwhile, the Diagnostics and Healthcare segment saw robust gains in Specialty Diagnostics, with steady contributions from transplant diagnostics and immunodiagnostics, resulting in overall stable growth for the year.

Strategic Acquisitions Fueling Expansion

Thermo Fisher’s growth approach centers on acquiring complementary technologies and businesses to enhance its portfolio. In 2025, the company allocated roughly $16.5 billion for investments, including $13 billion dedicated to mergers and acquisitions. These efforts are projected to generate $125 million in adjusted operating income synergies over the next five years, driven by both revenue growth and cost savings.

Notably, in October 2025, Thermo Fisher agreed to purchase Clario Holdings, Inc.—a leader in clinical trial endpoint data solutions—for $8.875 billion in cash. This acquisition is anticipated to boost adjusted EPS by about $0.45 within the first year. The deal further cements Thermo Fisher’s reputation as a trusted partner for pharmaceutical and biotech clients. Additionally, the company finalized the $4.1 billion acquisition of Solventum’s Purification & Filtration business in September 2025, integrating it into the Life Sciences Solutions division.

Challenges Facing Thermo Fisher

Impact of Currency Fluctuations

Thermo Fisher generates a significant portion of its revenue from international markets and aims to further expand globally. However, changes in foreign exchange rates can negatively affect reported sales and profits when converted to U.S. dollars for financial statements.

Image Source: Zacks Investment Research

As international sales continue to grow, the company’s exposure to currency volatility becomes more pronounced. While foreign exchange provided a 1% year-over-year benefit to sales in the fourth quarter of 2025, any reversal in currency trends could quickly impact reported growth.

Competitive Landscape

Thermo Fisher operates in a highly competitive environment, facing a diverse array of manufacturers and third-party distributors. Rapid technological advancements and evolving customer needs require ongoing investment in research and development to maintain a competitive edge.

Analyst Estimates and Stock Outlook

According to Zacks, the consensus estimate for Thermo Fisher’s 2026 earnings per share remains steady at $24.66 over the past month. Revenue projections for 2026 are set at $46.75 billion, representing a 4.9% increase from the previous year.

Other Noteworthy Medical Stocks

• Phibro Animal Health (PAHC): With an earnings yield of 5.5%, this company has consistently outperformed expectations, delivering an average earnings surprise of 20.2% over the last four quarters. Its shares have soared 117.5% over the past year, compared to a 15.1% decline for the industry. PAHC currently holds a Zacks Rank #1 (Strong Buy).
• Envista (NVST): Also rated Zacks Rank #1, Envista has an earnings yield of 4.8% and its stock has climbed 54% in the past year. The company has beaten earnings estimates in each of the last four quarters, with an average surprise of 16.4%.
• Align Technology (ALGN): Holding a Zacks Rank #2 (Buy), Align Technology is projected to achieve long-term earnings growth of 10.1%, outpacing the industry’s 9.1%. Its shares have risen 7.5% over the past year, compared to the industry’s 22% growth. ALGN has exceeded earnings expectations in three of the last four quarters, with an average surprise of 6.2%.

Zacks' Top Stock Picks

Zacks’ research team has identified five stocks with the potential to double in value in the coming months. Among these, the Director of Research, Sheraz Mian, has spotlighted a satellite-based communications company poised for significant growth as the space industry expands toward a trillion-dollar market. Analysts predict a major revenue surge for this firm in 2025. While not every top pick is a guaranteed winner, this one could outperform previous high-flyers like Hims & Hers Health, which soared over 200%.

For more expert recommendations, Zacks Investment Research is offering a free download of their “7 Best Stocks for the Next 30 Days.”

Free Stock Analysis Reports

• Align Technology, Inc. (ALGN)
• Thermo Fisher Scientific Inc. (TMO)
• Phibro Animal Health Corporation (PAHC)
• Envista Holdings Corporation (NVST)